Correction of residual hyperopia using light adjustable IOL technology

Article

Correction of residual hyperopia using light adjustable IOL technology

Correction of residual hyperopia using light adjustable IOL technology, from the Febraury 18 issue of the American Journal of Ophthalmology.

Please click here to read the abstract.

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
The office of the Agence Nationale de Sécurité du Médicament in Saint-Denis, France. ©HJBC – stock.adobe.com

PulseSight Therapeutics submits Clinical Trial Authorisation for phase I trial of PST-611

Hattie Hayes
January 16th 2025
Article

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

The ZEISS IOL Power Calculation Service. Providing guidance in complex cases

The ZEISS IOL Power Calculation Service. Providing guidance in complex cases

Patricia Casaer, MD ;Tobias Gutzeit, BSc
January 15th 2025
Article
PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A black-and-white photo of a handshake with the logos for Formycon, Klinge Biopharma and Teva over them.

Teva partners with Klinge Biopharma for commercialisation of Formycon’s FYB203 (biosimilar aflibercept)

Hattie Hayes
January 13th 2025
Article

The commercialisation agreement for the biosimilar to aflibercept (Eylea) covers Israel and major parts of Europe, excluding Italy

Bausch + Lomb launches its enVista Aspire monofocal and toric intraocular lenses in the European Union

Bausch + Lomb launches its enVista Aspire monofocal and toric intraocular lenses in the European Union

Martin David Harp
January 13th 2025
Article

The launch follows a CE Mark received in late 2024

© 2025 MJH Life Sciences

All rights reserved.